Health And Medicine

With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes. Read More

The Vanderbilt Institute for Clinical and Translational Research (VICTR), which provides comprehensive support for clinical and translational research at Vanderbilt University Medical Center (VUMC), has been named Administrative Coordinating Center (ACC) of a national effort to streamline the research response to life-threatening lung and heart problems caused by COVID-19. Read More

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered. Read More

Rebecca Ihrie and Jonathan Irish are leading the development of machine learning applications for brain cancer research. Read More

Zinc supplementation did not reduce mortality, cardiovascular risk, levels of inflammation or microbial translocation among people with heavy alcohol use living with HIV/AIDS, according to a Vanderbilt-led study. Read More

Vanderbilt University Medical Center is evaluating razuprotafib, a drug used to treat glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. Read More

The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found. Read More

A single mutation in one gene can impair inhibitory signaling in the brain and cause multiple types of seizures and behavioral abnormalities. Read More

The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm.  Read More

After discovering a new mechanism for DNA damage repair last year, Vanderbilt biochemists now provide direct evidence for how it works. Read More

Vanderbilt cell biologists have developed an unbiased, quantitative framework for evaluating single-cell data. Read More

On May 27, the All of Us Research Program launched the beta version of its cloud-based research platform, the Researcher Workbench. Read More

Biochemist Houra Merrikh has been named one of the nation’s rising stars in science for her work to reverse antimicrobial resistance. Read More

Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read More

Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of biochemistry, chemistry and pharmacology, has been named interim editor-in-chief of the journal "ACS Pharmacology & Translational Science." Read More

Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions. Read More

Vanderbilt researchers have developed what appears to be a simple and promising treatment for breast cancer metastasis. Read More

Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics. Read More

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read More

Staph bacteria may change the factor they use to activate blood clotting — to evade the immune response — a new study suggests. Read More